Item 7.01 Regulation FD Disclosure.

Osmotica Pharmaceuticals plc (the "Company") plans to hold an extraordinary general meeting of shareholders (the "Extraordinary General Meeting") on January 14, 2022 to seek shareholder approval to change the Company's name. In accordance with Rule 14a-8(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), the Company has set a deadline for the receipt of any shareholder proposals submitted pursuant to Rule 14a-8 under the Exchange Act ("Rule 14a-8") for inclusion in the Company's proxy materials relating to the Extraordinary General Meeting. In order for a proposal under Rule 14a-8 to be timely, it must be received by the Company's Secretary at the principal executive offices of the Company by November 27, 2021, which the Company has determined to be a reasonable time before the Company expects to print and send its proxy statement. Such proposals must also comply with the Company's Articles of Association and the rules of the Securities and Exchange Commission regarding the inclusion of shareholder proposals in proxy materials, and any such proposal may be omitted if not in compliance with applicable requirements. The address of the Company's principal executive offices is 400 Crossing Boulevard, Bridgewater, New Jersey 08807.

Shareholders wishing to propose matters to be considered at the Extraordinary General Meeting in the manner contemplated by the Company's Articles of Association must submit timely notice thereof to the Company's Secretary in order for such matters to be considered at the Extraordinary General Meeting. In accordance with Section 90.3 of the Company's Articles of Association, to be timely, such notice must be received at the registered office of the Company by November 27, 2021. Such proposals must also comply with all other requirements set forth in the Company's Articles of Association and applicable laws. The address of the Company's registered office is 25-28 North Wall Quay, Dublin 1, Ireland.

© Edgar Online, source Glimpses